Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

Company Pauses OV101 Program Based On NEPTUNE Results

 
• By Alaric DeArment
  
nerve cells, concept for neurodegenerative and neurological disease
Ovid shifts focus after Phase III Angelman syndrome study disappoints. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category